A recent study has found a potential link between the GLP-1 agonist medication semaglutide and nonarteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause irreversible vision loss. The investigation, led by Dr. Bradley Katz of the University of Utah, examined nine patients who experienced vision issues after taking semaglutide and tirzepatide.
The study found that seven of the participants developed NAION, with one experiencing a stroke in the retina and another developing swelling in both optic nerves. Researchers believe that rapid changes in blood sugar levels may contribute to these eye complications, causing an osmotic shift in fluid between blood vessels and cells in the eye.
While the exact mechanism is unclear, Dr. Katz emphasized that it’s essential for healthcare professionals to monitor patients taking GLP-1 medications for potential side effects on other areas of their health. He recommends that patients who experience vision changes while using these medications consult their doctor and have an eye exam.
Other experts in the field also weighed in on the study, stating that the rare association between semaglutide and NAION highlights the need for further research into the medication’s potential side effects. Dr. Mir Ali, a board-certified general surgeon, noted that the condition is extremely rare, making it challenging to pinpoint the exact cause. However, he emphasized the importance of being aware of all potential side effects and complications.
Dr. Howard Krauss, a surgical neuro-ophthalmologist, suggested that patients consider having an eye exam prior to initiating treatment with semaglutide or tirzepatide, especially if they have risk factors such as sleep apnea. The study’s findings underscore the importance of monitoring patients taking GLP-1 medications and encouraging them to report any vision changes or other symptoms to their healthcare provider.
Source: https://www.medicalnewstoday.com/articles/review-3-potentially-blinding-eye-conditions-glp-1-drugs-ozempic-mounjaro